Literature DB >> 16227329

Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.

H Nunes1, M Humbert, F Capron, M Brauner, O Sitbon, J-P Battesti, G Simonneau, D Valeyre.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a rare complication of sarcoidosis, although it is not uncommon in advanced disease.
METHODS: A retrospective series of 22 sarcoidosis patients (16 men) of mean (SD) age 46 (13) years with PH was divided into two groups depending on the absence (stage 0: n = 2, stage II: n = 4, stage III: n = 1) or presence (n = 15) of radiographic pulmonary fibrosis at the time of PH diagnosis.
RESULTS: In both groups PH was moderate to severe and there was no response to acute vasodilator challenge. In non-fibrotic cases no other cause of PH was found, suggesting a specific sarcoidosis vasculopathy, although no histological specimens were available. In cases with fibrosis there was no correlation between haemodynamics and lung volumes or arterial oxygen tensions, suggesting other mechanisms for PH in addition to pulmonary destruction and hypoxaemia. These included extrinsic arterial compression by lymphadenopathies in three cases and histologically proven pulmonary veno-occlusive disease in the five patients who underwent lung transplantation. Ten patients received high doses of oral prednisone for PH (stage 0: n = 1, stage II: n = 4 and stage IV: n = 5); three patients without pulmonary fibrosis experienced a sustained haemodynamic response. Survival of the overall population was poor (59% at 5 years). Mortality was associated with NYHA functional class IV but not with haemodynamic parameters or with lung function.
CONCLUSION: Two very different phenotypes of sarcoidosis combined with PH are observed depending on the presence or absence of pulmonary fibrosis. PH is a severe complication of sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227329      PMCID: PMC2080703          DOI: 10.1136/thx.2005.042838

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  33 in total

1.  Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis.

Authors:  I Chazova; I Robbins; J Loyd; J Newman; V Tapson; V Zhdaov; B Meyrick
Journal:  Eur Respir J       Date:  2000-01       Impact factor: 16.671

2.  Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids.

Authors:  D M Rodman; J Lindenfeld
Journal:  Chest       Date:  1990-02       Impact factor: 9.410

3.  Severe pulmonary hypertension in histiocytosis X.

Authors:  M Fartoukh; M Humbert; F Capron; S Maître; F Parent; C Le Gall; O Sitbon; P Hervé; P Duroux; G Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

4.  Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.

Authors:  I R Preston; J R Klinger; M J Landzberg; J Houtchens; D Nelson; N S Hill
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

5.  Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.

Authors:  A F Shorr; D L Helman; D B Davies; S D Nathan
Journal:  Eur Respir J       Date:  2005-05       Impact factor: 16.671

6.  Pulmonary veno-occlusive disease: a case series and new observations.

Authors:  B W Holcomb; J E Loyd; E W Ely; J Johnson; I M Robbins
Journal:  Chest       Date:  2000-12       Impact factor: 9.410

7.  Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function.

Authors:  M Abehsera; D Valeyre; P Grenier; H Jaillet; J P Battesti; M W Brauner
Journal:  AJR Am J Roentgenol       Date:  2000-06       Impact factor: 3.959

8.  Predicting mortality in patients with sarcoidosis awaiting lung transplantation.

Authors:  Andrew F Shorr; Darcy B Davies; Steven D Nathan
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

9.  Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease.

Authors:  Arnaud Resten; Sophie Maitre; Marc Humbert; Anne Rabiller; Olivier Sitbon; Frédérique Capron; Gérald Simonneau; Dominique Musset
Journal:  AJR Am J Roentgenol       Date:  2004-07       Impact factor: 3.959

10.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

Authors:  Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Ralph T Schermuly; Horst Olschewski; Norbert Weissmann; Andreas Gunther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

View more
  48 in total

Review 1.  Sarcoidosis and its otolaryngological implications.

Authors:  Katarzyna Mrówka-Kata; Dariusz Kata; Dariusz Lange; Grzegorz Namysłowski; Eugeniusz Czecior; Katarzyna Banert
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-09       Impact factor: 2.503

Review 2.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

3.  Pulmonary hypertension in Hodgkin's disease.

Authors:  Matthew Exline; Cynthia Magro; Thomas Lin; Namita Sood
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

Review 4.  Sarcoidosis--scientific progress and clinical challenges.

Authors:  Edward S Chen; David R Moller
Journal:  Nat Rev Rheumatol       Date:  2011-07-12       Impact factor: 20.543

Review 5.  Rare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature.

Authors:  Alice Rossi; Maurizio Zompatori; Patrick Tchouante Tchouanhou; Michele Amadori; Massimiliano Palazzini; Elisa Conficoni; Nazzareno Galiè; Venerino Poletti; Giampaolo Gavelli
Journal:  Radiol Med       Date:  2013-11-15       Impact factor: 3.469

Review 6.  Pathology of Sarcoidosis.

Authors:  Giulio Rossi; Alberto Cavazza; Thomas V Colby
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

7.  Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.

Authors:  Aggeliki Rapti; Vasileios Kouranos; Elias Gialafos; Konstantina Aggeli; John Moyssakis; Anastasios Kallianos; Charalampos Kostopoulos; Ourania Anagnostopoulou; Petros P Sfikakis; Athol U Wells; George E Tzelepis
Journal:  Lung       Date:  2012-12-11       Impact factor: 2.584

8.  Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft.

Authors:  R Saggar; D J Ross; R Saggar; D A Zisman; A Gregson; J P Lynch; M P Keane; S Samuel Weigt; A Ardehali; B Kubak; C Lai; D Elashoff; M C Fishbein; W D Wallace; J A Belperio
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

9.  Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.

Authors:  Esam H Alhamad; Majdy M Idrees; Mohammed O Alanezi; Ahmad A Alboukai; Shaffi Ahmad Shaik
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

10.  Sarcoidosis-induced pericarditis in a patient with portopulmonary hypertension: a case report.

Authors:  Olga Giouleme; Panagiotis Anagnostis; Kalliopi Patsiaoura; Themistoklis Vasiliadis; Nikolaos Grammatikos; Nikitas Kakavas; Alexander Mpoumponaris; Nikolaos Eugenidis; Elias Basayannis
Journal:  Cases J       Date:  2009-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.